BCRD and BSPAR ETN studies

Discovering more about new treatments for children and young people with Juvenile Idiopathic Arthritis.

What are the studies about?

Two studies called Biologics for Children with Rheumatic Diseases (BCRD) and BSPAR Etanercept Study (BSPAR ETN) are underway at hospitals throughout the UK to look at the safety and effectiveness of biologic and biosimilar treatment for Juvenile Idiopathic Arthritis (JIA).

As part of the studies, long term follow-up information regarding changes to the disease and any newer illnesses is collected to determine the safety and effectiveness of these types of treatments.

What is biologic therapy?

Take a look at this short video to learn all you need to know about biologic therapy.

 

Can I join the study?

Children and young people under the age of 18 are able to join the studies if they meet the following criteria:

Diagnosis
A diagnosis of active Juvenile Idiopathic Arthritis.
Informed consent
Informed consent within six months of starting the registration treatment.
Biologic/biosimilar treated group

Participants starting etanercept (Enbrel or any etanercept biosimilar) to be registered with BSPAR ETN.

Participant starting any biologic or biosimilar therapy (excluding Enbrel or any etanercept biosimilar) to be registered with BCRD.

Participant can have received other biologics/biosimilars in the past.

Methotrexate-treated group
Recruitment to this group is now closed.

Information for participants


Find out how to participate in our studies.

Information for healthcare professionals


Find all the resources you need to process information about participants in the BCRD and BSPAR ETN studies.